All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PT001
Therapeutic Area: Immunology Product Name: PT001
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
The research, done in collaboration with St Vincent’s Institute of Medical Research in Australia and funded by JDRF and the JDRF T1D Fund, showed that PT001 treatment delayed the onset of hyperglycemia in a mouse model of Type 1 diabetes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Jubilant Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 15, 2021
Details:
Collaboration aims to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $240.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2021
Details:
Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ST266
Therapeutic Area: Immunology Product Name: ST266
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2021
Details:
The studies demonstrated that the complete ST266 secretome is required to obtain the full neuroprotective and myelin-protective effects in the experimental autoimmune encephalomyelitis (EAE) mouse model of optic neuritis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HT-005 Z-PODS
Therapeutic Area: Immunology Product Name: HT-005
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Zylo Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Details:
Results from the study demonstrated that the novel HT-005 loaded Z-pods™ were effective to reduce skin plaques associated with CLE, with statistical significance demonstrated in the overall average skin score as well as individual skin scores on the head and scapula.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HT-005 Z-PODS
Therapeutic Area: Immunology Product Name: HT-005
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Zylo Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
The animal study supports that HT-005 has the potential to be an effective treatment for cutaneous manifestations of lupus, a significant unmet medical need.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PT001
Therapeutic Area: Immunology Product Name: PT001
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
Pandion utilizes its TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform to create antibody-based candidates that target known control nodes in the immune system.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
